immuno-oncology Archives | Page 50 of 65 | NanoString

Home » immuno-oncology » Page 50

November 25, 2018 / Biomedicines

Dissecting the Immune Landscape of Acute Myeloid Leukemia

Davidson-Moncada J et al.,

November 20, 2018 / Oncoimmunology.

Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models

Newsted D. et al.,

November 13, 2018 / Cancer

The antitumor effects of entinostat in ovarian cancer require adaptive immunity

Smith H.J. et. al.,

November 2, 2018 / PLoS ONE

Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

Yu J.W. et. al.,

November 2, 2018 / JCI Insight

Sitravatinib potentiates immune checkpoint blockade in refractory cancer models

Du W. et. al.,

November 1, 2018 / Ann. Oncol.

Immunological differences between primary and metastatic breast cancer

Szekely B. et. al.,

October 29, 2018 / Oncoimmunology.

Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort

Wang Q et al.,

October 27, 2018 / Curr Treat Options Oncol

Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits

Zandberg DP et al.,

October 19, 2018 / JAMA Oncol

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

Adams S et al.,

October 12, 2018 / Science

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu R. et. al.,

October 12, 2018 / Science

Pan-tumor genomic biomarkers for PD-1 checkpoint blockadeâ€“based immunotherapy

Cristescu R. et. al.,

October 11, 2018 / Cell

Evolution of Metastases in Space and Time under Immune Selection

Angelova M. et. al.,

Previous 1 … 48 49 50 51 52 … 65 Next